Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events

Vera E. R. Asscher*, Quirine van der Vliet, Karen van der Aalst, Anniek van der Aalst, Eelco C. Brand, Andrea E. van der Meulen-de Jong, Bas Oldenburg, Marieke J. Pierik, Bas van Tuyl, Nofel Mahmmod, P. W. Jeroen Maljaars, Herma H. Fidder, Dutch ICC

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2331-2338
Number of pages8
JournalInternational Journal of Colorectal Disease
Volume35
Issue number12
Early online date28 Aug 2020
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Crohn's disease
  • Ulcerative colitis
  • Biologicals
  • Elderly
  • Co-morbidity
  • ANTI-TNF THERAPY
  • ELDERLY-PATIENTS
  • CROHNS-DISEASE
  • CHEMOTHERAPY
  • INFECTIONS
  • INFLIXIMAB
  • COLITIS
  • CANCER
  • SAFETY
  • RISK

Cite this